INTRODUCTION
============

Familial hemophagocytic lymphohistiocytosis (HLH) is an inherited autosomal recessive disease that is characterized by defective natural killer (NK) cells and T-cell cytotoxicity and manifests as fever, cytopenia, and tissue hemophagocytosis. Genes known to be altered in familial HLH include *PRF1*, *UNC13D*, *STX11*, and *STXBP2*, which cause familial HLH subtypes 2 to 5, respectively. Subtype 4 is caused by mutations in the syntaxin 11 gene (*STX11*) located on chromosome 6q24. The identification of aberrations in *STX11* and the abnormal expression of *STX11* as the cause of HLH were first reported in Kurdish children \[[@B1]\]. Since then, mutations of *STX11* have been reported in approximately 10% of patients with familial HLH, the vast majority of whom have Turkish/Kurdish ethnicity \[[@B2]\]. We report a novel *STX11* mutation in familial HLH. It was identified in a Korean child, which is the first report in Korea and also in the Far East.

CASE REPORT
===========

A 33-month-old boy born to non-consanguineous Korean parents was admitted for intermittent fever lasting one week and abdominal distension. Complete blood count revealed a white blood cell count of 2.09×10^9^/L, hemoglobin level of 10.5 g/dL, and a platelet count of 58×10^9^/L. Serologic study showed fibrinogen levels of 209 mg/dL; triglycerides, 157 mg/dL; and ferritin, 371 ng/mL. Abdominal sonography indicated hepatosplenomegaly, and bone marrow study revealed hemophagocytosis with histiocytic hyperplasia. The test for plasma Epstein-Barr virus DNAemia was negative. The patient\'s fever and poor general condition persisted, and under the diagnosis of HLH, dexamethasone and etoposide chemotherapy according to the HLH-2004 regimen was started \[[@B3]\]. The patient received unrelated hematopoietic stem cell transplantation from a 1-allele mismatched donor after undergoing busulfan, etoposide, cyclophosphamide, and antithymocyte globulin-based conditioning. He is currently disease free 16 months after transplantation with complete donor chimerism.

Genetic study for mutations in *PRF1*, *UNC13D*, and *STX11*, performed through direct sequencing of exons and exon-intron boundaries of genomic DNA extracted from peripheral blood leukocytes, revealed a novel homozygous missense mutation in the *STX11*: c.650T\>C, p.Leu217Pro ([Fig. 1](#F1){ref-type="fig"}). Genetic studies of the parents and older sister were performed, and the mother was found to be a carrier of the *STX11* mutation, whereas the father and sister were negative for *STX11* mutation. Short tandem repeat analysis confirmed the biological relationship of the father and mother with the patient.

To study the possibility of allele dropout, we designed several additional primer sets avoiding single nucleotide polymorphism (SNP) sites. The mutation found in the patient was unaffected by allele dropout (i.e. non-amplification of one of the alleles). Long-range PCR covering 9kb of genomic DNA from a portion of intron 1 to exon 2 identified no large deletion breakpoints. Additionally, SNP array with the Sureprint G3 human comparative genomic hybridization (CGH)+SNPMicroarray4x180K kit (Agilent Technologies, Santa Clara, CA, USA) confirmed no large heterozygous deletion in *STX11* or uniparental disomy in chromosome 6.

Genotype analysis was performed with 19 SNP markers in an approximately 9-kb region from part of intron1 (c.-5-7000) to part of the 3\'untranslated region (UTR; c.^\*^2000) surrounding c.650 of *STX11*. One haplotype bearing c.650 of *STX11* was confirmed to originate from the maternal allele, but the other haplotype harboring the same mutation was suspicious for uniparental disomy (UPD) because it was only partially concordant with the paternal allele ([Fig. 2](#F2){ref-type="fig"}, orange bar).

This novel mutation was not listed in dbSNP (<http://www.ncbi.nlm.nih.gov/projects/SNP/>) or 1,000 Genomes (<http://browser.1000genomes.org/>). Because database and literature reviews showed that c.650T\>C had not been previously reported in *STX11* ([Fig. 3A](#F3){ref-type="fig"}), we performed a control study and found that c.650T\>C was not detected in 192 healthy controls in the Korean population. Comparative genomic analysis with Evola (<http://www.h-invitational.jp/evola/>) demonstrated that the Leu217 residue is conserved across all 12 vertebrate species ([Fig. 3B](#F3){ref-type="fig"}). Bioinformatics analyses with SIFT (<http://sift.jcvi.org/>) and Polyphen-2 (<http://genetics.bwh.harvard.edu/pph2/>) showed that p.Leu217Pro was predicted to be not tolerated and probably damaging.

DISCUSSION
==========

Since the initial report associating *STX11* mutation with familial HLH, the majority of reported patients with *STX11* mutation have been of Turkish or Middle Eastern ethnicity \[[@B4][@B5]\]. Korean studies found the *UNC13D* mutation to be predominant among patients with familial HLH but identified no patients with *STX11* mutation \[[@B6]\]. Evaluations undertaken in both Japan and China also failed to identify familial HLH patients with *STX11* mutation \[[@B7][@B8]\]. Hence, our patient is not only the first familial HLH patient with *STX11* mutation of Korean ethnicity but possibly also the first such patient reported from the Far East. Mutations outside the predominant ethnicity have tended to be novel \[[@B9][@B10]\].

Of particular note, our patient was homozygous for the *STX11* mutation despite having only one parent who carried the mutation. Although neither large deletion nor allele drop was identified, genotype analysis demonstrated that the homozygous c.650T\>C may have resulted from duplication of a maternal (unimaternal) chromosomal region and concurrent loss of the other paternal allele. This interstitial UPD is likely associated with meiotic errors such as two crossover events \[[@B11]\].

The various genetic mutations involved in familial HLH result in different clinical disease courses. Patients with *PRF1* mutations have earlier disease onset, often during infancy, whereas *STX11* mutations may result in onset at a significantly older age \[[@B4][@B5]\]. Among patients with *STX11* mutations, those with a nonsense mutation may present during infancy, whereas those with biallelic missense mutations may show symptoms at older ages \[[@B9]\].

Our study underscores the hypothesis that *STX11* mutation screening in patients with presumed familial HLH is diagnostically relevant regardless of ethnicity. A cumulative study of these novel mutations and their effects on specific protein interactions may lead to greater understanding of how abnormal *STX11* expression results in deficient cytotoxic function.
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